Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape

2 Jan 2023

Abstract excerpt

Messenger RNA (mRNA)-based vaccine platforms used for the development of mRNA-1273 and BNT162b2 have provided a robust adaptable approach to offer protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, as variants of concern (VoCs), such as omicron and associated sub-variants, emerge, boosting strategies must also adapt to keep pace with the changing landscape. Heterologous...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to RNA Interference and Gene Delivery
Share to SARS-CoV-2 and COVID-19 Research
Share to Viral Infections and Immunology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36629006
DOI: 10.1080/21645515.2022.2153532

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscapePMID 36629006Read ↗

Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccinesSemantic proximity Read ↗

Effectiveness of Mrna Booster Vaccination Against Mild and Severe COVID-19 During Delta and Omicron Variant Circulation in Germany: An Analysis of National Surveillance DataSemantic proximity Read ↗

Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseasesSemantic proximity Read ↗

From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine LandscapeSemantic proximity Read ↗

Ad26.COV2.S priming provides a solid immunological base for mRNA-based COVID-19 booster vaccinationSemantic proximity Read ↗

A Bivalent Omicron-containing Booster Vaccine Against Covid-19Semantic proximity Read ↗

COVID‐19 Vaccine Efficacy and the Evidence on BoostersSemantic proximity Read ↗

COVID-19 mRNA Booster Vaccines Elicit Strong Protection Against SARS-CoV-2 Omicron Variant in Patients with CancerSemantic proximity Read ↗

Antibody Response of Heterologous vs Homologous mRNA Vaccine Boosters Against the SARS-CoV-2 Omicron Variant: Interim Results from the PRIBIVAC Study, A Randomized Clinical TrialSemantic proximity Read ↗

mRNA Vaccine Technology Beyond COVID-19Semantic proximity Read ↗

Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19Semantic proximity Read ↗

Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccineSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.